$CRBP
Corbus Pharmaceuticals Holdings, Inc. Stock $crbp

$crbp Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000119312515289161 Filed on August 13, 2015

Income Statement

Concept	2015 Q3	2015 Q2	2014 Q2
Revenue	$170.5K	$113.6K	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$790.0K	$970.0K	$290.0K
YoY Change	113.51%	234.48%	1350.0%
% of Gross Profit
Research & Development	$1.630M	$1.707M	$169.4K
YoY Change	260.14%	907.57%	-5.87%
% of Gross Profit
Depreciation & Amortization	$20.00K	$0.00	$0.00
YoY Change	100.0%
% of Gross Profit
Operating Expenses	$2.425M	$2.676M	$464.3K
YoY Change	196.43%	476.43%	132.15%
Operating Profit	-$2.255M	-$2.563M	-$464.3K
YoY Change	175.59%	451.95%
Interest Expense	$0.00	$393.00	$11.23K
YoY Change	-100.0%	-96.5%	-212.32%
% of Operating Profit
Other Income/Expense, Net	$1.037K	$155.00	-$40.31K
YoY Change	-99.35%	-100.38%
Pretax Income	-$2.250M	-$2.560M	-$500.0K
YoY Change	240.91%	412.0%	138.1%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$2.254M	-$2.563M	-$504.6K
YoY Change	241.69%	407.83%	140.29%
Net Earnings / Revenue	-1322.28%	-2255.04%
Basic Earnings Per Share
Diluted Earnings Per Share	-$64.71K	-$95.17K	-$19.79K
COMMON SHARES
Basic Shares Outstanding	31.99M shares	26.05M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q3	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.20M	$9.243M	$8.500M
YoY Change	76.0%	8.74%
Cash & Equivalents	$13.10M	$9.243M	$8.504M
Short-Term Investments	$0.00	$0.00
Other Short-Term Assets	$100.0K	$200.0K	$0.00
YoY Change
Inventory
Prepaid Expenses		$249.1K
Receivables
Other Receivables
Total Short-Term Assets	$13.30M	$9.492M	$8.500M
YoY Change	76.01%	11.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$0.00	$58.73K	$0.00
YoY Change	-100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00
YoY Change
Total Long-Term Assets	$0.00	$72.46K	$0.00
YoY Change	-100.0%
TOTAL ASSETS
Total Short-Term Assets	$13.30M	$9.492M	$8.500M
Total Long-Term Assets	$0.00	$72.46K	$0.00
Total Assets	$13.30M	$9.565M	$8.500M
YoY Change	74.32%	12.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$728.0K	$1.069M	$200.0K
YoY Change	50.83%	434.61%
Accrued Expenses	$466.1K	$390.0K	$200.0K
YoY Change	735.57%	95.02%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00		$400.0K
YoY Change	-100.0%
Total Short-Term Liabilities	$1.876M	$2.341M	$900.0K
YoY Change	205.69%	160.1%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$200.0K
YoY Change		-100.0%
Other Long-Term Liabilities	$300.0K	$500.0K
YoY Change
Total Long-Term Liabilities	$300.0K	$500.0K	$200.0K
YoY Change		150.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.876M	$2.341M	$900.0K
Total Long-Term Liabilities	$300.0K	$500.0K	$200.0K
Total Liabilities	$2.160M	$2.796M	$1.100M
YoY Change	251.98%	154.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$10.78M	-$8.525M
YoY Change	240.38%
Common Stock	$3.761K	$3.075K
YoY Change	45.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.17M	$6.769M	$7.500M
YoY Change
Total Liabilities & Shareholders Equity	$13.33M	$9.565M	$8.500M
YoY Change	74.77%	12.53%

Cashflow Statement

Concept	2015 Q3	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	-$2.254M	-$2.563M	-$504.6K
YoY Change	241.69%	407.83%	140.29%
Depreciation, Depletion And Amortization	$20.00K	$0.00	$0.00
YoY Change	100.0%
Cash From Operating Activities	-$2.480M	$20.00K	-$320.0K
YoY Change	327.59%	-106.25%	77.78%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$20.00K	-$10.00K
YoY Change	-100.0%	100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$20.00K	-$10.00K
YoY Change	-100.0%	100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	6.420M	4.270M	8.670M
YoY Change	-2045.45%	-50.75%
NET CHANGE
Cash From Operating Activities	-2.480M	20.00K	-320.0K
Cash From Investing Activities	0.000	-20.00K	-10.00K
Cash From Financing Activities	6.420M	4.270M	8.670M
Net Change In Cash	3.940M	4.270M	8.340M
YoY Change	-510.42%	-48.8%	-4733.33%
FREE CASH FLOW
Cash From Operating Activities	-$2.480M	$20.00K	-$320.0K
Capital Expenditures	$0.00	-$20.00K	-$10.00K
Free Cash Flow	-$2.480M	$40.00K	-$310.0K
YoY Change	367.92%	-112.9%	72.22%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-504608
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	28464
CY2015Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1787899
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	2940369
CY2015Q2	us-gaap	Assets Assets	9564751
CY2015Q2	us-gaap	Marketable Securities MarketableSecurities	0
CY2014Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0325	pure
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	31990364	shares
CY2015Q2	crbp	Potential Future Milestone Payments PotentialFutureMilestonePayments	3750000
CY2013Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	301778	shares
CY2014Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	18414
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8504172
CY2014Q2	crbp	Debt Instrument Imputed Interest Rate DebtInstrumentImputedInterestRate	0.07	pure
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3716170	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.95
CY2015Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30745627	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	0.67
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2015Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	8896848	shares
CY2015Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30745627	shares
CY2015Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	56511
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	113023
CY2015Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	0
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	6769136
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	28048
CY2015Q2	us-gaap	Deferred Revenue DeferredRevenue	1136364
CY2015Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	200000
CY2015Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	15291395
CY2015Q2	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	0
CY2015Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	681616
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1069213
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	390038
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8525334
CY2015Q2	us-gaap	Liabilities Liabilities	2795615
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9564751
CY2015Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	454748
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	3075
CY2015Q2	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	21946
CY2015Q2	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	13730
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2340867
CY2015Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2014Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	5862733
CY2015Q2	us-gaap	Cash Cash	218084
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	58725
CY2015Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	13730
CY2015Q2	us-gaap	Assets Current AssetsCurrent	9492296
CY2015Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	35209
CY2015Q2	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	9025069
CY2015Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	249143
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9243153
CY2015Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	19310
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7949972
CY2015Q2	crbp	Computer Hardware And Software Gross ComputerHardwareAndSoftwareGross	26152
CY2015Q2	crbp	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedAggregateIntrinsicValue	95108
CY2015Q2	crbp	Warrants Weighted Average Exercise Price WarrantsWeightedAverageExercisePrice	0.99
CY2015Q2	crbp	Deferred Revenue Gross DeferredRevenueGross	1250000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	303020
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3556691	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.83
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25938332	shares
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25938332	shares
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	10287214
CY2014Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	0
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	344160
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	249491
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4427075
CY2014Q4	us-gaap	Liabilities Liabilities	593651
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6456384
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	2594
CY2014Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10405
CY2014Q4	us-gaap	Notes Payable NotesPayable	144389
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	593651
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2014Q4	us-gaap	Notes Payable Current NotesPayableCurrent	144389
CY2014Q4	us-gaap	Assets Assets	6600773
CY2014Q4	us-gaap	Marketable Securities MarketableSecurities	0
CY2014Q4	us-gaap	Cash Cash	10974
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	54044
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	13728
CY2014Q4	us-gaap	Assets Current AssetsCurrent	6533001
CY2014Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	27960
CY2014Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	6251471
CY2014Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	270556
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6262445
CY2014Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	19310
CY2014Q4	crbp	Computer Hardware And Software Gross ComputerHardwareAndSoftwareGross	17179
CY2015Q2	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	1250000
CY2015Q2	us-gaap	Adjustment For Amortization AdjustmentForAmortization	1250000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-461663
	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.66	pure
	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0125	pure
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15199333	shares
	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14532561	shares
	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P3Y11M19D
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8009
	us-gaap	Net Income Loss NetIncomeLoss	-620587
	us-gaap	Operating Income Loss OperatingIncomeLoss	-569942
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-50645
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	48380
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-425
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	20207
	us-gaap	Investment Income Interest InvestmentIncomeInterest	623
	us-gaap	Share Based Compensation ShareBasedCompensation	26412
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	28448
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	8100
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	8201152
	us-gaap	Operating Expenses OperatingExpenses	569942
	us-gaap	Interest Expense InterestExpense	22395
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-8009
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	8670824
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	231360
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8670824
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	74078
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	338582
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1108609
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	27193
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
	us-gaap	Paid In Kind Interest PaidInKindInterest	22395
	us-gaap	Depreciation Depreciation	180
	crbp	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-620587
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	us-gaap	Nature Of Operations NatureOfOperations	<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>1.</b></td> <td valign="top" align="left"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" align="justify"><b>NATURE OF OPERATIONS</b></p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <b><i>Business</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt" align="justify">Corbus Pharmaceuticals Holdings, Inc. (“CPHI” or “the Company”) is a clinical stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets and raising capital. The Company’s business is subject to significant risks and uncertainties and the Company will be dependent on raising substantial additional capital before it becomes profitable and it may never achieve profitability.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt" align="justify">In the opinion of management of the Company, the accompanying unaudited condensed consolidated interim financial statements reflect all adjustments (which include only normal recurring adjustments) necessary to present fairly, in all material respects, the consolidated financial position of the Company as of June 30, 2015 and the results of its operations and cash flows for the three and six months ended June 30, 2015 and 2014. The December 31, 2014 condensed consolidated balance sheet was derived from audited financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. It is suggested that these condensed consolidated financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, filed on February 10, 2015. The results of operations for such interim periods are not necessarily indicative of the operating results for the full fiscal year.</p> </div>
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1260480
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P3Y
	us-gaap	Interest Paid InterestPaid	1108
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4097995
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-264
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	2
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12613018	shares
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001595097
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y5M27D
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <b><i>Concentrations of Credit Risk</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt" align="justify">The Company has no significant off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other hedging arrangements. The Company may from time to time have cash in banks in excess of Federal Deposit Insurance Corporation insurance limits.</p> </div>
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.91
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	1219696	shares
	dei	Entity Registrant Name EntityRegistrantName	CORBUS PHARMACEUTICALS HOLDINGS, INC.
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	192500	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.11
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.91
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-464297
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt" align="justify">The process of preparing financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and changes in estimates may occur. The most significant estimates are related to stock based compensation, the value of derivative instruments and the accrual of research and clinical obligations.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 6px">  </p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt" align="justify">Prior to the registration of its common stock and the subsequent public listing of the common stock, the Company had granted stock options at exercise prices not less than the fair value of its common stock as determined by the board of directors, with input from management. The Company’s board of directors determined the estimated fair value of the common stock based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector and the historic prices at which the Company sold shares of preferred stock.</p> </div>
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	33021	shares
	dei	Trading Symbol TradingSymbol	CRBP
	crbp	Warrants Exercised To Purchase Common Stock Shares WarrantsExercisedToPurchaseCommonStockShares	4598129	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	26434174	shares
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y2M19D
	us-gaap	Depreciation Depreciation	11541
	crbp	Operating Lease Terms OperatingLeaseTerms	P3Y
	crbp	Class Of Warrant Or Right Issued ClassOfWarrantOrRightIssued	0	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y7M24D
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	144389
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16222
	us-gaap	Net Income Loss NetIncomeLoss	-4098259
	us-gaap	Revenues Revenues	113636
CY2014Q4	us-gaap	Debt Instrument Term DebtInstrumentTerm	P8M
CY2014Q4	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	24293
CY2014Q4	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	192000
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-21413
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1108
	us-gaap	Share Based Compensation ShareBasedCompensation	602863
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1136364
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	27450
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2980708
	us-gaap	Operating Expenses OperatingExpenses	4211631
	us-gaap	Interest Expense InterestExpense	1372
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-16222
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	4257410
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4398000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2430686
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4401799
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	140547
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	4402000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1780945
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	925053
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	1250000
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
	crbp	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-4098259
	crbp	Class Of Warrant Or Right Cancelled ClassOfWarrantOrRightCancelled	0	shares
	crbp	Deferred Tax Assets Valuation Allowance Percentage DeferredTaxAssetsValuationAllowancePercentage	1.00	pure
	crbp	Issuance Of Common Stock Upon Exercise Of Options And Warrants IssuanceOfCommonStockUponExerciseOfOptionsAndWarrants	4807295	shares
	crbp	Warrants Weighted Average Remaining Contractual Term WarrantsWeightedAverageRemainingContractualTerm	P4Y
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22071172	shares
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-40311
CY2014Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	309
CY2014Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	578
CY2014Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	29966
CY2014Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	8100
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	464297
CY2014Q2	us-gaap	Interest Expense InterestExpense	11232
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	169443
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	294854
CY2014Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2014Q2	crbp	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-504608
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	26901100	shares
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-2562541
CY2015Q2	us-gaap	Revenues Revenues	113636
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2562696
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	155
CY2015Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	548
CY2015Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	13725
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	2676332
CY2015Q2	us-gaap	Interest Expense InterestExpense	393
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1707256
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	969076
CY2015Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2015Q2	crbp	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-2562541

Files In Submission

Name	View Source	Status
0001193125-15-289161-index-headers.html	Edgar Link	pending
0001193125-15-289161-index.html	Edgar Link	pending
0001193125-15-289161.txt	Edgar Link	pending
0001193125-15-289161-xbrl.zip	Edgar Link	pending
crbp-20150630.xml	Edgar Link	completed
crbp-20150630.xsd	Edgar Link	pending
crbp-20150630_cal.xml	Edgar Link	unprocessable
crbp-20150630_def.xml	Edgar Link	unprocessable
crbp-20150630_lab.xml	Edgar Link	unprocessable
crbp-20150630_pre.xml	Edgar Link	unprocessable
d84624d10q.htm	Edgar Link	pending
d84624dex311.htm	Edgar Link	pending
d84624dex312.htm	Edgar Link	pending
d84624dex321.htm	Edgar Link	pending
d84624dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRBP
Corbus Pharmaceuticals Holdings, Inc. Stock $crbp

2015 Q3 Form 10-Q Financial Statement

#000119312515289161 Filed on August 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRBP Corbus Pharmaceuticals Holdings, Inc. Stock $crbp

2015 Q3 Form 10-Q Financial Statement

#000119312515289161 Filed on August 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRBP
Corbus Pharmaceuticals Holdings, Inc. Stock $crbp